"Your health and safety are always our top priority. To help you protect yourself and your loved ones, we’ve gathered the most important information and guidance on the coronavirus and COVID-19. Go to our website. You have many ways to get care without leaving the comfort of your home - including an e-visit, phone, video appointments, and email. This allows you to still get great care while helping to address the community spread of COVID-19. If you’re concerned about your specific health condition, call 1-833-KP4CARE (1-833-574-2273) (TTY 711) to talk to a licensed care provider 24/7. For answers to your general questions about COVID-19, call our new information line for Kaiser Permanente members at 1-877-813-7297."

During the past decade, Kaiser Permanente-Irvine conducted 96 clinical trials. In the 10-year time frame, 96 clinical trials started and 45 clinical trials were completed, i.e. on average, 46.9% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 31 clinical trials were completed. i.e. 88.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kaiser Permanente-Irvine" #1 sponsor was "National Cancer Institute (NCI)" with 61 trials, followed by "SWOG Cancer Research Network" with 29 trials sponsored, "Alliance for Clinical Trials in Oncology" with 6 trials sponsored, "NRG Oncology" with 5 trials sponsored and "NSABP Foundation Inc" with 5 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kaiser Permanente-Irvine" #1 collaborator was "National Cancer Institute (NCI)" with 52 trials as a collaborator, "NRG Oncology" with 10 trials as a collaborator, "Canadian Cancer Trials Group" with 5 trials as a collaborator, "Astellas Pharma US, Inc." with 2 trials as a collaborator and "Genentech, Inc." with 2 trials as a collaborator. Other collaborators include 24 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "Kaiser Permanente-Irvine" are "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Stage IV Lung Cancer AJCC v8" (8 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials), "Stage IVA Lung Cancer AJCC v8" (7 trials) and "Stage IVB Lung Cancer AJCC v8" (7 trials). Many other conditions were trialed in "Kaiser Permanente-Irvine" in a lesser frequency.

Most popular intervention types in "Kaiser Permanente-Irvine" are "Drug" (96 trials), "Other" (81 trials), "Biological" (57 trials), "Procedure" (32 trials) and "Behavioral" (5 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (44 trials), "Quality-of-Life Assessment" (29 trials), "Questionnaire Administration" (21 trials), "Biospecimen Collection" (19 trials) and "Computed Tomography" (19 trials). Other intervention names were less common.

The vast majority of trials in "Kaiser Permanente-Irvine" are 101 trials for "All" genders, 24 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Kaiser Permanente-Irvine". undefined are not yet recruiting, 31 are recruiting, 57 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Kaiser Permanente-Irvine, 1 suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Kaiser Permanente-Irvine, 0 "Phase 1" clinical trials were conducted, 54 "Phase 2" clinical trials and 67 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".